...
首页> 外文期刊>Medical science monitor : >Performance of Screening Tools in Detecting Major Depressive Disorder among Patients with Coronary Heart Disease: A Systematic Review
【24h】

Performance of Screening Tools in Detecting Major Depressive Disorder among Patients with Coronary Heart Disease: A Systematic Review

机译:筛查工具在检测冠心病患者主要抑郁症中的作用:系统评价

获取原文
           

摘要

ABSTRACT Background: Major depressive disorder (MDD) is common in patients with coronary heart disease (CHD) and there is no consensus on the optimal screening tool for use in identifying MDD. This study aimed to systematically review the performance of various screening tools in the identification of MDD. Material and Methods: Eligible studies published before 31 Dec 2013 were identified from the following databases: Ovid Medline, EMBASE, PsycINFO, Scopus, Cochrane Library, CINAHL Plus, and Web of Science. Results: Eight studies aiming to identify MDD in CHD patients were included, and there were 10 self-reporting questionnaires (such as PHQ-2, PHQ-9, PHQ categorical algorithm, HADS-D, BDI, BDI-II, BDI-II-cog, CES-D, SCL-90, 2 simple yeso items) and 1 observer rating scale (Ham-D). For MDD alone, the sensitivity and specificity of various screening tools at the validity and optimal cut-off point varied from 0.34 [0.19, 0.52] to 0.96 [0.78, 1.00] and 0.69 [0.65, 0.73] to 0.97 [0.93, 0.99]. Results showed PHQ-9 (≥10), BDI-II (≥14 or ≥16), and HADS-D (≥5 or ≥4) were widely used for screening MDD in CHD patients. Conclusions: There is no consensus on the optimal screening tool for MDD in CHD patients. When evaluating the performance of a screening tool, balancing the high sensitivity and negative predictive value (NPV) between specificity and positive predictive value (PPV) for screening or diagnostic purpose should be considered. After screening, further diagnosis, appropriate management, and necessary referral may also improve cardiovascular outcomes.
机译:摘要背景:重度抑郁症(MDD)在冠心病(CHD)患者中很常见,对于用于鉴定MDD的最佳筛查工具尚无共识。这项研究旨在系统地审查各种筛选工具在鉴定MDD中的性能。材料和方法:从以下数据库中鉴定了2013年12月31日之前发表的合格研究:Ovid Medline,EMBASE,PsycINFO,Scopus,Cochrane图书馆,CINAHL Plus和Web of Science。结果:包括八项旨在鉴定CHD患者MDD的研究,并提供了10份自我报告问卷(例如PHQ-2,PHQ-9,PHQ分类算法,HADS-D,BDI,BDI-II,BDI-II) -cog,CES-D,SCL-90、2个简单的是/否项目)和1个观察者等级量表(Ham-D)。仅对于MDD,各种筛选工具在有效性和最佳截止点的敏感性和特异性从0.34 [0.19,0.52]到0.96 [0.78,1.00]和0.69 [0.65,0.73]到0.97 [0.93,0.99]不等。结果显示,PHQ-9(≥10),BDI-II(≥14或≥16)和HADS-D(≥5或≥4)被广泛用于CHD患者的MDD筛查。结论:关于CHD患者MDD的最佳筛查工具尚无共识。在评估筛选工具的性能时,应考虑在特异性和阳性预测值(PPV)之间的高灵敏度和阴性预测值(NPV)之间进行筛选或诊断。筛查后,进一步诊断,适当治疗和必要的转诊也可能会改善心血管疾病的预后。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号